Six patients with progressive disease after conventional treatments (colon adenocarcinoma (n = 2), triple-negative breast adenocarcinoma, anal squamous cell carcinoma, PSMA-negative prostate adenocarcinoma and signet ring cell colon carcinoma) received a mean of 1.6 GBq [213Bi]Bi-FAPI-46. This evidence concerns the gene FOLH1 and prostate adenocarcinoma.